Objectives: Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmoticcontrolled release oral delivery system methylphenidate (OROS MPH) treatment response.
A ttention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in childhood. Worldwide prevalence of ADHD has been estimated to be 5.3%, 1 and Korean prevalence was reported as 1.9% to 13.2%. [2] [3] [4] [5] Genetic influences on ADHD have been investigated in many studies. It has been found that 20% to 30% of parents or siblings of proband have the same disease, 6, 7 and biological relatives show a higher rate of ADHD than adoptive relatives. 8 The heritability of ADHD was estimated to be approximately 76% in 20 twin studies. 9 These findings support genetic etiology in ADHD.
Methylphenidate is the first-line drug for ADHD treatment. The efficacy of methylphenidate has been previously demonstrated by many well-designed studies and meta-analyses. 10, 11 The efficacy of osmotic-controlled release oral delivery system methylphenidate (OROS MPH) has also been documented by many studies. [12] [13] [14] However, treatment outcomes of methylphenidate varied among individuals, 15 and the predictors of treatment response have not yet been conclusively demonstrated. Many studies have been made to explore association of genetic variation with methylphenidate response, but diverse methods were used, and the result was not conclusive.
Norepinephrine transporter (NET) plays a potential role in pathogenesis of ADHD, and it was suggested that NET gene (SLC6A2) was related with MPH response. SLC6A2 is located in 16q12.2, and about 300 single nucleotide polymorphisms (SNPs) were investigated. 16 It was reported that rs3785157, rs998424, rs3785143, rs11568324, and −3081(A/T) in SLC6A2 were associated with ADHD. [17] [18] [19] [20] A genome-wide association study reported that 2 SNPs (rs17841329, rs192303) in SLC6A2 might be related with MPH response. 21 However, in a genomewide association study for adult ADHD, SLC6A2 was not associated with MPH response. 22 Studies for investigating candidate genes of ADHD have begun to focus on genes besides major catecholamine systems in recent times. 23 The synaptosomal-associated protein of the 25 kDa (SNAP-25) is one of those novel genes. SNAP-25 is a part of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE), which plays a role in axonal growth, synaptic plasticity, docking of a synaptic vesicle, and exocytosis. 24, 25 The SNAP-25 gene is located on chromosome 20p11.2. 26 A study reported that Coloboma mouse with deletion of SNAP-25 expressed hyperactivity, which suggested that the SNAP-25 gene was associated with ADHD. 27 Previous research reported that some SNPs of the SNAP-25 gene polymorphism are associated with ADHD. 25 It was initially identified that there was biased transmission of the haplotypes of rs3746544 and rs10151312 polymorphism in the 3′ untranslated region of the SNAP-25 gene in ADHD. 28, 29 Feng et al 30 investigated biased transmission of the allele of 4 polymorphisms (rs6039806, rs362987, rs362549, and rs362998) in Canadian families with ADHD by using the transmission disequilibrium test. In a Korean case-controlled association study, TG genotype of 1065 T>G polymorphism was related with ADHD. 31 This study also reported that 1069 T>C polymorphism was monomorphic in the Korean population. Faraone et al 9 conducted a metaanalysis in which 1065 T>G polymorphism was significantly associated with ADHD (odds ratio, 1.19; 95% confidence interval, 1.03-1.38). In another meta-analysis including 4 transmission disequilibrium tests 28, 30, 32 and 3 case-controlled haplotype-based haplotype relative risk studies, 31, 33, 34 only 1065 T>G polymorphism was significantly associated with ADHD. 23 In this meta-analysis, it was suggested that the T allele of 1065 T>G polymorphism was significantly involved with ADHD. 23 Although some studies have suggested an association between the SNAP-25 gene and ADHD as mentioned previously, there is a paucity of research that examined the association between the SNAP-25 gene and methylphenidate response. In preschoolers with ADHD, subjects with 1065 T>G T homozygous showed a medium positive effect on methylphenidate treatment, whereas 1069 T>C T homozygous showed a negative effect. 35 This finding was not replicated in a subsequent study that examined the role of candidate genes for methylphenidate response in ADHD among children aged 6 to 17 years. 36 Latrophilin 3 gene (LPHN3) is another novel candidate gene for ADHD. LPHN3 encodes a member of latrophilin subfamily of G-protein coupled receptors and influences on exocytosis of neurotransmitter. 37 Family association study with large number explored that 3 SNPs (rs6551665, rs1947274, rs2345039) were involved with ADHD. 38 Among these SNPs, rs6551665 was suggested to be related with MPH response. Association of rs6551665, rs1947274, and MPH treatment response was noted in another family-based association study. 39 Our study aimed to examine association between SLC6A2, SNAP-25, and LPHN3 and OROS MPH treatment response. We selected rs192303 and rs3785143 in SLC6A2; rs3746544 (1065 T>G) in SNAP-25 gene; and rs6551665, rs1947274, and rs2345039 in LPHN3, which were suggested to be related with MPH response or associated with ADHD in genome-wide association study.
MATERIALS AND METHODS

Participants
Children and adolescents with ADHD were recruited from child and adolescent clinics of 3 university hospitals in South Korea. Inclusion criteria were as follows: (1) ADHD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; (2) ages 6 to 18 years; (3) no history of psychostimulants; (4) baseline Korean version of the ADHD rating scale (K-ARS) score of 19 or more; and (5) Korean race/ethnicity. The exclusion criteria were as follows: (1) presence of neurological disease including seizure or significant physical illness; (2) pervasive developmental disorder, mental retardation, mood disorder, or psychotic disorder requiring concomitant psychotropic medication; (3) undergoing additional psychiatric treatment including psychosocial treatment and other psychotropic medications; and (4) lack of informed consent.
This study was approved by the institutional review boards at the 3 centers, and informed consent was obtained from the participants and their parents or guardians.
Diagnostic Procedures
We diagnosed ADHD and comorbid disorders by using the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version, Korean Version. 40 This instrument is a semistructured interview for diagnosis of psychiatric disorders in children. The Korean version has good reliability and validity. 40 
Clinical Symptoms Assessment
Korean Version of the ADHD Rating Scale
The ARS is an instrument for assessment of symptoms of ADHD. 41 It is a 4-point scale and consists of 18 items measuring inattention and hyperactivity-impulsivity dimensions. The validity and reliability of the Korean version proved to be acceptable. 42 
Clinical Global Impression-Improvement
Clinical Global Impression-Improvement (CGI-I) is a tool for the assessment of symptom improvement with a 7-point scale. 43 The CGI-I scale rates items as 1, very much improvement; 2, much improvement; 3, minimally improvement; 4, no change; 5, minimally worse; 6, much worse; and 7, very much worse.
Definition of Treatment Response
We assessed treatment response with 2 efficacy measures. We first defined a good response group as those for whom the K-ARS score at 8 weeks of trial was more than 50% lower than the baseline scores. 44 A secondary efficacy measure was defined as CGI-I score at 8 weeks of 1 or 2. Finally, we defined treatment response group as both CGI-I and change of K-ARS score.
DNA Direct Sequencing
Genomic DNA was isolated form whole blood with a purification kit (FUJIFILM Corporation, Tokyo, Japan). The polymerase chain reaction (PCR) method was used to amplify the 11 fragments of the IL12B gene. The final volume of the PCR was 10 μL, consisting of 10 ng of DNA, 0.5 uM of each primer pair, 0.25 mM deoxyribonucleotide triphosphates, 3 mM MgCl 2 , 1 μL 1Â reaction buffer, and 0.25 unit DiaStar Taq DNA polymerase (5 unit/μL) (SolGent Co Ltd, Daejeon, South Korea). The PCR conditions used were as follows: initial denaturation at 94°C for 5 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C to 65°C for 30 seconds, initial extension at 72°C for 30 to 60 seconds, and final extension at 72°C for 10 minutes. The PCR products were purified using a Mul-tiScreen 384-PCR filter plate (Millipore, Billerica, Mass). The purified products were then sequenced using a BigDye terminator cycle sequencing kit and an ABI 3730xl automated sequencer (Applied Biosystems, Foster City, Calif). The sequencing primers were the same as those used for the PCR amplification. Mutation analyses were performed using Phred, Phrap, Consed, and Polyphred 5.04 softwares (http://droog.mbt.washington.edu/PolyPhred.html).
SNaPShot Assay
The SNaPshot assay was performed according to the manufacturer's instructions (ABI Prism SNaPShot Multiplex Kit; Foster City, Calif). Analysis was carried out using GeneMapper software (version 4.0; Applied Biosystems).
Briefly, the genomic DNA flanking the SNP of interest was amplified with PCR reaction with forward and reverse primer pairs and standard PCR reagents in 10 μL reaction volume, containing 10 ng of genomic DNA, 0.5 pM of each oligonucleotide primer, 1 μL of 10X PCR buffer, 250 μM dNTP (2.5 mM each), and 0.25 unit DiaStar Taq DNA polymerase (5 unit/μL) (SolGent Co Ltd). The PCR reactions were carried out as follows: 10 minutes at 95°C for 1 cycle, and 35 cycles at 95°C for 30 seconds, 55°C for 1 minute, 72°C for 1 minute, followed by 1 cycle of 72°C for 10 minutes. After amplification, the PCR products were treated with 1 unit each of shrimp alkaline phosphatase (USB Corporation, Cleveland, Ohio) and exonuclease I (USB Corporation) at 37°C for 75 minutes and 72°C for 15 minutes to purify the amplified products. One microliter of the purified amplification products was added to a SNaPshot multiplex-ready reaction mixture containing 0.15 pmol of genotyping primer for primer extension reaction. The primer extension reaction was carried out for 25 cycles at 96°C for 10 seconds, 50°C for 5 seconds, and 60°C for 30 seconds. The reaction products were treated with 1 unit of shrimp alkaline phosphatase at 37°C for 1 hour and 72°C for 15 minutes to remove excess fluorescent dye terminators. One microliter of the final reaction samples containing the extension products were added to 9 μL of Hi-Di formamide (ABI, Foster City, Calif). The mixture was incubated at 95°C for 5 minutes, followed by 5 minutes on ice, and then analyzed by electrophoresis in an ABI Prism 3730xl DNA analyzer. Analysis was carried out using GeneMapper software (version 4.0; Applied Biosystems).
Statistical Analysis
Descriptive statistics were obtained to evaluate demographic and clinical characteristics. We compared genotype frequencies between the good and poor response groups by using the χ 2 test or Fisher's exact test. Treatment response was defined as change in K-ARS scores and CGI-I scores. The 3 genotype frequencies in each candidate gene were compared according to treatment responses. We also analyzed genotype frequencies according to classification of treatment response group by both change of K-ARS and CGI-I. Finally, we conducted haplotype analysis for SLC6A2 and LPHN3.
The level of significance was 0.05, and SPSS 19.0 was used for the statistical analyses (SPSS Inc, Chicago, Ill).
RESULTS
Demographic and Clinical Characteristics
One hundred thirty-nine subjects were enrolled in our study. One hundred twenty (86.3%) were male, and 19 (13.7%) were female. The participants' mean (SD) age was 10.0 (2.8). One hundred two (73.4%) had combined type ADHD, 28 (20.1%) had inattentive type, and 3 (2.2%) had hyperactive-impulsive type; 63.3% of patients had one or more comorbidities. The mean (SD) dose of OROS MPH at the eighth week of treatment was 31.0 (9.2) mg ( Table 1 ). The frequency of each genotype was in Hardy-Weinberg equilibrium except rs192303.
Association of SNAP-25 With OROS MPH Response
Analysis of the 1065 T>G in SNAP-25 showed that TT was present in 79 (56.8%), TG was in 51 (36.7%), and GG was in 9 (6.5%) of the participants ( Table 2) . With the good response group defined by K-ARS scores, 33.3% of the subjects with GG genotype showed a good response, whereas 74.7% of those with TT genotype and 72.5% of those with TG genotype showed good responses (P=0.034, Table 2 ). When we defined treatment response as K-ARS and CGI-I, good response rate of each genotype was 22.2%, 65.8%, and 70.6% (P=0.018, Table 2 ). However, when we defined response group by CGI-I scores at 8 weeks, there was no significant difference of OROS MPH response among 3 SNAP-25 genotypes. The findings of 1065 T>G were not significant adjusting for multiple comparison.
Association of SLC6A2 and LPHN3 With OROS MPH Response
In analysis of SLC6A2, there was a significant association between rs192303 and OROS MPH treatment response, when treatment response was defined by CGI-I (P=0.009, Table 2 ). When we adjusted for multiple comparison, this finding was not statistically significant.
We examined 3 SNPs (rs6551665, rs1947274, rs2345039) of LPHN3, and no SNP was associated with OROS MPH treatment response ( Table 2 ).
Haplotype Analysis of SLC6A2 and LPHN3
We used Haploview 4.2 software to analyze linkage disequilibrium haplotype blocks. Two SNPs of LPHN3, rs6551665 and rs1947274, were constructed as 1 block (D'=1, r 2 >0.7, logarithm of the odds > 3) and 3 haplotypes. Single nucleotide polymorphisms of SLC6A2 did not compose of haplotype block. There was no association between the 3 haplotypes of rs6551665, rs1947274 block and OROS MPH treatment response (Table 3 ).
DISCUSSION
Our study investigated the association between OROS MPH treatment response and SNAP-25, SLC6A2, and LPHN3 gene variants in ADHD. Results indicated that SNAP-25 gene and SLC6A2 were related to OROS MPH treatment responses.
Previous studies that examined association of candidate genes with methylphenidate response in ADHD have focused on major catecholamine systems such as dopamine and norepinephrine. Our study investigated to explore association between OROS MPH response and other genetic variants beyond catecholamine systems. In animal models for pharmacogenetic research of ADHD, studies with the Coloboma mouse have suggested the role of the SNAP-25 gene in methylphenidate response. The expression of the SNAP-25 gene modified the release of neurotransmitters, 45 and amphetamine was more effective in the Coloboma mouse than methylphenidate. 27 As far as we know, our study was the first to examine the association between genetic variants of SNAP-25 gene with methylphenidate response in an Asian population. Our result supports that the SNAP-25 gene might have neurobiological importance in ADHD. However, we could not explore how SNAP-25 1065 T>G had an effect on OROS MPH response. The 1065 T>G polymorphism is in the 3′ untranslated region of the genes, and the 1065 T>G polymorphism is less likely to influence encoding of protein variants and SNAP-25 expression. 28 We could postulate the role of the 1065 T>G polymorphism on the methylphenidate response based on a previous study that examined the association of the SNAP-25 gene with hemodynamic change by using functional near-infrared spectroscopy. 46 In that study, subjects with the 1065 T>G TT polymorphism did not show brain hemodynamic variability during MPH medication. Low hemodynamic change might be associated with less favorable MPH response in subjects with 1065 T>G TT polymorphism. 46 In our study, rs192303 in SLC6A2 polymorphism was related to OROS MPH response. Mick et al 21 investigated that rs17481329 and rs192303 of SLC6A2 polymorphism were associated with MPH response, although it was not a significant correction for multiple comparison. Rs192303 is located in SLC6A2 intron 1, and combination of intron 1 and 5′ upstream sequence supported high-level transcription of noradrenergic cell. 47 We could infer that this SNP had direct function for modulating expression of SLC6A2 or this had high linkage disequilibrium with functional variants that influence on expression of SLC6A2.
LPHN3 was not related with OROS MPH treatment response in this study. It was not consistent with previous study findings. 38, 39, 48 LPHN3 is localized in the cerebral cortex, caudate nucleus, amygdala, and cerebellum, and it was reported that these regions were related with ADHD. 48 On the bases of these findings, the concern with LPHN3 in ADHD has been growing, and further study for exploring association between LPHN3 and MPH response is needed. Our study has some limitations. First, this was not a randomized placebo-controlled trial. We could not control the confounding factor of the placebo response. Second, comorbidities were not considered in our study. It has been reported that comorbidities in ADHD such as oppositional defiant disorder and conduct disorder could influence on treatment response in ADHD pharmacogenetic studies. 49 Thus, it might be possible that comorbidities had an effect on our result. Third, genetic variants might moderate dose response, but we did not examine gene-by-dose interactions.
Pharmacogenetic studies could play an important role in investigating the cause and predictors of variable responses. In addition, they could help clinicians choose optimal medications for each individual. Although our study has some limitations as mentioned previously, it suggests that there is an association of the SNAP-25 gene and SLC6A2 with OROS MPH response. Future research with larger samples is needed in which covariance that may influence methylphenidate response is controlled.
CONCLUSIONS
We investigated the association between candidate gene and OROS MPH treatment response in ADHD. 1065 T>G of SNAP-25 gene was associated with OROS MPH response when treatment response was defined by change of K-ARS score or combined change of K-ARS and CGI-I. Rs192303 in SLC6A2 was also related to OROS MPH treatment response when it was defined by CGI-I.
